News
NSPR
--
0.00%
--
InspireMD Files Shelf for Up to About 1.3 Million Common Shares on Behalf of Selling Stockholder
MT Newswires · 5d ago
InspireMD代表销售股东申请搁置最多约130万股普通股。
MT Newswires · 5d ago
InspireMD社、販売株主に代わって最大約130万株の普通株式の発行を申請
MT Newswires · 5d ago
BRIEF-Inspiremd Files Prospectus Related To Offering, Resale Of Up To 1.3 Mln Shares By Selling Stockholder
reuters.com · 5d ago
Best Penny Stocks To Buy Right Now? 4 To Watch For April 2021
Mar 29, 2021 (Penny Stocks via COMTEX) -- Are These Hot Penny Stocks To Buy Right Now? There is a lot of excitement involving penny stocks this year. Much of...
Penny Stocks · 03/29 18:43
Global Neurovascular Stent Market Size 2021 By Share, Growth Analysis, Industry Share, End-User Demand, Size Estimation, Growth Factors, Production, Industry Statistics, Overview, and Forecast Report till 2025
The Express Wire · 03/26 06:19
Neurovascular Stent Market Size, Top Companies, Regional Growth Overview and Growth Factors Details by Regions, Types and Applications| Impact of COVID-19, Forecast to 2025
Mar 23, 2021 (The Expresswire) -- The "Neurovascular Stent Market" research report presents an in-depth assessment of trends affecting industry dynamics with...
The Express Wire · 03/23 07:13
BRIEF-InspireMD CEO Marvin Slosman Issues Letter To Stockholders
reuters.com · 03/22 11:56
InspireMD CEO Marvin Slosman Issues Letter to Fellow Stockholders Urging Support of the Company's Plans to List its Common Stock on Nasdaq at the Upcoming Special Meeting of Stockholders
InspireMD, Inc. (NYSE:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today issues a message to stockholders from InspireMD CEO,
Benzinga · 03/22 11:54
Best Penny Stocks To Buy Now? These 4 Are Turning Heads
Mar 18, 2021 (Penny Stocks via COMTEX) -- Do These Biotech Penny Stocks Have Market Potential Right Now? Recently biotech penny stocks have been performing...
Penny Stocks · 03/18 13:31
8-K: InspireMD, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/17 11:58
BRIEF-Inspiremd Inc Says Special Meeting Of Stockholders Scheduled For And Convened On March 17 Has Been Adjourned To April 14, At 1130 A.M., Local Time
reuters.com · 03/17 11:07
Neurointerventional Devices Market Size Remuneration to Surpass USD 4.6 billion by 2027
Mar 17, 2021 (Market Insight Reports) -- Selbyville, Delaware, According to the research report titled 'Global Neurointerventional Devices Market Size study,...
Market Insight Reports · 03/17 09:55
COVID-19 Outbreak-Global Neurovascular Stents Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
Mar 16, 2021 (Heraldkeepers) -- Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control...
Heraldkeepers · 03/16 13:19
8-K: InspireMD, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/10 21:17
The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 8)
Benzinga · 03/09 13:08
InspireMD Q4 EPS $(0.10) Misses $(0.08) Estimate, Sales $158.00K Miss $1.00M Estimate
InspireMD (AMEX:NSPR) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 82.46 percent increase over losses of $(0.57) per share from the same
Benzinga · 03/09 11:36
BRIEF-InspireMD Reports Q4 Loss Per Share $0.10
reuters.com · 03/09 11:34
InspireMD EPS misses by $0.03, misses on revenue
InspireMD (NSPR): Q4 GAAP EPS of -$0.10 misses by $0.03.Revenue of $0.16M (-84.2% Y/Y) misses by $0.94M.Press Release
Seekingalpha · 03/09 11:33
InspireMD Announces Fourth Quarter and Year-End 2020 Financial Results
Management to host investor conference call today, March 9, at 8:30am ETTEL AVIV, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused...
GlobeNewswire · 03/09 11:30
Webull provides a variety of real-time NSPR stock news. You can receive the latest news about INSPIREMD through multiple platforms. This information may help you make smarter investment decisions.
About NSPR
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.